Revolution Medicines, Inc. $RVMD
Clinical trial pipeline · active industry-sponsored Phase 1/2 to Phase 3 trials · updated 2026-11-13
ACTIVE TRIALS12
PHASE 3 / 2-37
RECRUITING11
READOUTS ≤12 MONTHS2
READOUT SLIPPED >6 MO50%
Delay Index: of 6 active trials registered more than a year ago, 3 have moved their primary completion (readout) date by more than 6 months since first registration (median +16.6 months). See all sponsors →
Open Revolution Medicines, Inc. on the live radar map →| TRIAL | PHASE | STATUS | CONDITION | N | PRIMARY COMPLETION |
|---|---|---|---|---|---|
| RASolute 302 NCT06625320 |
P3 | Active, not recruiting | Pancreatic Cancer; PDAC | 500 | 2026-06 |
| RMC-6236 NCT05379985 |
P1/2 | Recruiting | Non-small Cell Lung Cancer (NSCLC); Colorectal Cancer (CRC) | 754 | 2027-05-31 (+36 mo) |
| RMC-6291 NCT06162221 |
P1/2 | Recruiting | Non-Small Cell Lung Cancer, NSCLC; KRAS, NRAS, HRAS-mutated NSCLC | 616 | 2027-06 |
| RASolve 301 NCT06881784 |
P3 | Recruiting | NSCLC (Non-small Cell Lung Cancer); Non-Small Cell Lung Cancer | 590 | 2027-12-01 |
| RASolute 303 NCT07491445 |
P3 | Recruiting | Pancreatic Cancer; Pancreatic Cancer Metastatic | 900 | 2028-06 |
| RMC-6236 NCT06445062 |
P1/2 | Recruiting | Colorectal Cancer; CRC | 1130 | 2028-09-30 (+17 mo) |
| Elironrasib NCT06128551 |
P1/2 | Recruiting | Non-Small Cell Lung Cancer (NSCLC); Colorectal Cancer | 534 | 2028-12 (+24 mo) |
| RASolute 305 NCT07621718 |
P3 | Recruiting | Pancreatic Cancer; Pancreatic Cancer Metastatic | 670 | 2028-12-30 |
| RASolute 309 NCT07805954 |
P3 | Recruiting | Pancreatic Cancer; Pancreatic Cancer Metastatic | 400 | 2029-03 |
| Daraxonrasib NCT07397338 |
P1/2 | Recruiting | Advanced Solid Tumors; Metastatic Solid Tumors | 370 | 2029-05 |
| RASolute 304 NCT07252232 |
P3 | Recruiting | Pancreatic Cancer; PDAC | 500 | 2029-05-10 |
| RASolve 308 NCT07777822 |
P3 | Recruiting | NSCLC; Non-small Cell Lung Cancer | 430 | 2029-10 |